N-Aminophthalimidin | 23990-34-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: N-Aminophthalimidin
• 英文别名: 2-aminoisoindolin-1-one；1H-Isoindol-1-one, 2-amino-2,3-dihydro-；2-amino-3H-isoindol-1-one
• CAS: 23990-34-3
• 化学式: C₈H₈N₂O
• 分子量: 148.164
• InChiKey: BQAVZKPCEICBRV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-Aminophthalimidin 、 3甲酰利福平霉素 以 四氢呋喃 为溶剂， 反应 0.5h， 生成 3-[(1-oxo-1,3-dihydro-isoindol-2-ylimino)-methyl]-rifamycin
  参考文献：
  名称：

  Cricchio; Carniti; Cietto, Farmaco, Edizione Scientifica, 1975, vol. 30, # 9, p. 704 - 720

  摘要：

  DOI：
• 作为产物：
  描述：

  N-(t-butyloxycarbonyl)-2-aminoisoindolin-1-one 在 盐酸 作用下， 以 乙酸乙酯 为溶剂， 以94%的产率得到N-Aminophthalimidin
  参考文献：
  名称：

  研究3-苯并异噻唑酮，异吲哚等位异构体与活化的乙炔之间的反应：用于构建生物活性分子的杂环骨架的合成

  摘要：

  在三苯基膦存在下，对苯并[ d ]异噻唑-3-酮，2-氨基苯并[ d ]异噻唑-3-酮，其等排物2-氨基异吲哚-1-酮和活化的乙炔之间的反应的研究导致了我们合成可能对构建生物活性分子具有吸引力的新型杂环化合物。一锅法PPh 3促进的串联反应，与乙炔二羧酸盐和二苯甲酰基乙炔一起，得到了新的三环吡唑并稠合的苯并异噻唑。PPh 3苯并异噻唑酮和丙酸甲酯之间的促进反应通过异噻唑环扩环提供了1,4-苯并噻唑并5-5衍生物。这些研究为苯并异噻唑酮化学提供了新的见解，并描述了对新颖衍生物的简单和原始合成途径。

  DOI：

  10.1002/jhet.2197

文献信息

• [EN] INHIBITORS OF CBL-B AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE CBL-B ET LEURS PROCÉDÉS D'UTILISATION
  申请人：NURIX THERAPEUTICS INC

  公开号：WO2019148005A1

  公开（公告）日：2019-08-01

  Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo.

  揭示了用于抑制泛素蛋白酶体途径中的E3酶Cbl-b的化合物、组合物和使用方法。这些化合物、组合物和方法可用于调节免疫系统，治疗适合免疫系统调节的疾病，并用于体内、体外或体外细胞的治疗。
• Taxol enhancer compounds
  申请人：Shionogi BioResearch Corp.

  公开号：US20030045518A1

  公开（公告）日：2003-03-06

  One embodiment of the present invention is a compound represented by the Structural Formula (I): 1 Y is a covalent bond of a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both >C=Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. Preferably, Y is a covalent bond or —C(R 7 R 8 )—. R 1 is an aliphatic group, a substituted aliphatic group, a non-aromatic hetereocyclic group, or a substituted non-aromatic hetereocyclic group, R 2 -R 4 are independently —H, an aliphatic group, a substituted aliphatic group, a non-aromatic hetereocyclic group, a substituted non-aromatic hetereocyclic group, an aryl group or a substituted aryl group, or R 1 and R 3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R 2 and R 4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. R 5 -R 6 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R 7 and R 8 are each independently —H, an aliphatic or substituted aliphatic group, or R 7 is —H and R 8 is a substituted or unsubstituted aryl group, or, R 7 and R 8 , taken together, are a C2-C6 substituted or unsubstituted alkylene group. Z is ═O or ═S. Also disclosed are pharmaceutical compositions comprising the compound of the present invention and a pharmaceutically acceptable carrier or diluent.

  本发明的一个实施例是由结构式（I）表示的化合物：1Y是取代或未取代的直链碳氢基团的共价键。此外，Y与其结合的两个>C=Z基团一起，是取代或未取代的芳香基团。优选，Y是共价键或—C(R7R8)—。R1是脂肪基团、取代脂肪基团、非芳香杂环基团或取代非芳香杂环基团，R2-R4独立地为—H、脂肪基团、取代脂肪基团、非芳香杂环基团、取代非芳香杂环基团、芳基团或取代芳基团，或R1和R3与其结合的碳和氮原子，和/或R2和R4与其结合的碳和氮原子，形成一个可选择地与芳香环融合的非芳香杂环环。R5-R6独立地为—H、脂肪基团、取代脂肪基团、芳基团或取代芳基团。R7和R8各自独立地为—H、脂肪或取代脂肪基团，或者R7为—H且R8为取代或未取代的芳基团，或者，R7和R8一起为C2-C6取代或未取代的烷基基团。Z是═O或═S。还披露了包含本发明化合物和药学上可接受的载体或稀释剂的药物组合物。
• Synthesis of taxol enhancers
  申请人：Shionogi BioResearch Corp.

  公开号：US20030069225A1

  公开（公告）日：2003-04-10

  Disclosed is a method of preparing a thiohydrazide product compound from a hydrazide starting compound. The hydrazide starting compound is represented by Structural Formula (I): 1 The thiohydrazide product compound is represented by Structural Formula (II): 2 In Structural Formulas (I)-(II), R 1 and R 2 are independently an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R 1 and R 2 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. When R 2 is an aryl group or a substituted aryl group, then R 5 is a hydrazine protecting group; and when R 2 is an aliphatic or substituted aliphatic group, then R 5 is —H or a hydrazine protecting group. R 10 is —H or a substituted or unsubstituted alkyl group. The method comprising the step of reacting the starting compound with a thionylating reagent.

  本发明涉及一种从一个酰肼起始化合物制备硫代酰肼产物化合物的方法。所述酰肼起始化合物由结构式（I）表示：1 所述硫代酰肼产物化合物由结构式（II）表示：2 在结构式（I）-（II）中，R1和R2分别独立地是脂肪基，取代的脂肪基，芳基或取代的芳基，或者R1和R2连同它们连接的碳和氮原子形成一个非芳杂环环，该杂环可以与一个芳环融合。当R2是芳基或取代的芳基时，R5是一个肼保护基；当R2是脂肪基或取代的脂肪基时，R5是-H或肼保护基。R10是-H或取代或未取代的烷基。所述方法包括将起始化合物与硫酰化试剂反应的步骤。
• Discovery of Potent Inhibitors against P-Glycoprotein-Mediated Multidrug Resistance Aided by Late-Stage Functionalization of a 2-(4-(Pyridin-2-yl)phenoxy)pyridine Analogue
  作者：Yao Ma、Dawei Yin、Jingjia Ye、Xiduan Wei、Yameng Pei、Xueyuan Li、Guangxu Si、Xuan-Yu Chen、Zhe-Sheng Chen、Yi Dong、Feng Zou、Wei Shi、Qianqian Qiu、Hai Qian、Gang Liu

  DOI：10.1021/acs.jmedchem.0c00337

  日期：2020.5.28

  designed and synthesized to discover potential inhibitors against P-glycoprotein-mediated multidrug resistance aided by late-stage functionalization of a 2-(4-(pyridin-2-yl)phenoxy)pyridine analogue. A novel class of potent P-gp reversal agents were investigated, and a lead compound 37 was identified as a potent P-gp reversal agent with strong bioactivity and outstanding affinity for P-gp.

  SIS3是Smad3的特异性抑制剂，其抑制TGFβ1诱导的Smad3的磷酸化。在本文中，设计并合成了多种SIS3衍生物，以发现在2-（4-（吡啶-2-基）苯氧基）吡啶类似物的后期官能化的辅助下，针对P-糖蛋白介导的多药耐药性的潜在抑制剂。研究了一类新型的强力P-gp逆转剂，铅化合物37被确定为强力P-gp逆转剂，具有强大的生物活性和对P-gp的出色亲和力。
• Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents
  申请人：Berger Markus

  公开号：US20050090559A1

  公开（公告）日：2005-04-28

  The invention relates to pentanol derivatives of general formula I that are substituted by quinazoline, quinoxaline, cinnoline, indazole, phthalazine, naphthyridine, benzothiazole, dihydroindolone, dihydroisoindolone, benzimidazole or indole, a process for their production and their use as anti-inflammatory agents.

  该发明涉及一种通式I的戊醇衍生物，其被喹唑啉、喹喔啉、茜啉、吲唑啉、菲啶啉、萘啉、苯并噻唑、二氢吲哚酮、二氢异吲哚酮、苯并咪唑或吲哚取代，以及它们的制备方法和它们作为抗炎药物的用途。